Pershing Edward has filed 170 insider transactions across 1 company since September 2022.
Most recent transaction: a grant/award of 50000 shares of PROVECTUS BIOPHARMACEUTICALS, INC. ($PVCT) on March 25, 2026.
Activity breakdown: 3 open-market purchases and 0 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| March 25, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,235,000.0000 | 420,279,879 | 4.22% | 0.01% |
| March 20, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 130000 | $0.00 | 1,185,000.0000 | 420,279,879 | 9.89% | 0.03% |
| March 20, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 49067 | $0.00 | 2,710,054.0000 | 420,279,879 | 1.84% | 0.01% |
| March 12, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 35000 | $0.00 | 1,315,000.0000 | 420,279,879 | 2.73% | 0.01% |
| March 5, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 20000 | $0.00 | 1,280,000.0000 | 420,279,879 | 1.59% | 0.00% |
| Feb. 26, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 15000 | $0.00 | 1,260,000.0000 | 420,279,879 | 1.20% | 0.00% |
| Feb. 19, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,370,000.0000 | 420,279,879 | 3.79% | 0.01% |
| Feb. 20, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 125000 | $0.00 | 1,245,000.0000 | 420,279,879 | 9.12% | 0.03% |
| Feb. 20, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 47180 | $0.00 | 2,660,987.0000 | 420,279,879 | 1.81% | 0.01% |
| Feb. 12, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 30000 | $0.00 | 1,320,000.0000 | 420,279,879 | 2.33% | 0.01% |
| Feb. 9, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | P | Series D-1 Convertible Preferred Stock | 34940 | $2.86 | 2,613,807.0000 | 420,279,879 | 1.35% | 0.01% |
| Feb. 5, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 10000 | $0.00 | 1,290,000.0000 | 420,279,879 | 0.78% | 0.00% |
| Jan. 30, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 1,280,000.0000 | 420,279,879 | 7.25% | 0.02% |
| Jan. 30, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 37744 | $0.00 | 2,578,867.0000 | 420,279,879 | 1.49% | 0.01% |
| Jan. 28, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 15000 | $0.00 | 1,380,000.0000 | 420,279,879 | 1.10% | 0.00% |
| Jan. 16, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 1,365,000.0000 | 420,279,879 | 6.83% | 0.02% |
| Jan. 16, 2026 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 37744 | $0.00 | 2,541,123.0000 | 420,279,879 | 1.51% | 0.01% |
| Dec. 11, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 45000 | $0.00 | 1,465,000.0000 | 420,279,879 | 3.17% | 0.01% |
| Dec. 5, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 75000 | $0.00 | 1,420,000.0000 | 420,279,879 | 5.58% | 0.02% |
| Nov. 26, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 70000 | $0.00 | 1,345,000.0000 | 420,279,879 | 5.49% | 0.02% |
| Nov. 20, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 30000 | $0.00 | 1,275,000.0000 | 420,279,879 | 2.41% | 0.01% |
| Nov. 13, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 30000 | $0.00 | 1,245,000.0000 | 420,279,879 | 2.47% | 0.01% |
| Nov. 6, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 35000 | $0.00 | 1,215,000.0000 | 420,279,879 | 2.97% | 0.01% |
| Oct. 30, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 65000 | $0.00 | 1,180,000.0000 | 420,279,879 | 5.83% | 0.02% |
| Oct. 23, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 20000 | $0.00 | 1,115,000.0000 | 420,279,879 | 1.83% | 0.00% |
| Oct. 16, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 18880 | $0.00 | 2,503,379.0000 | 420,279,879 | 0.76% | 0.00% |
| Oct. 16, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,095,000.0000 | 420,279,879 | 4.37% | 0.01% |
| Oct. 10, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 60000 | $0.00 | 1,145,000.0000 | 420,279,879 | 5.53% | 0.01% |
| Oct. 3, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 35000 | $0.00 | 1,085,000.0000 | 420,279,879 | 3.33% | 0.01% |
| Sept. 30, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 175000 | $0.00 | 1,050,000.0000 | 420,279,879 | 14.29% | 0.04% |
| Sept. 30, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 66052 | $0.00 | 2,484,499.0000 | 420,279,879 | 2.73% | 0.02% |
| Sept. 18, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 35000 | $0.00 | 1,325,000.0000 | 420,279,879 | 2.71% | 0.01% |
| Sept. 19, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 37760 | $0.00 | 2,418,447.0000 | 420,279,879 | 1.59% | 0.01% |
| Sept. 19, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 1,225,000.0000 | 420,279,879 | 7.55% | 0.02% |
| Sept. 11, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 35000 | $0.00 | 1,290,000.0000 | 420,279,879 | 2.79% | 0.01% |
| Sept. 4, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 30000 | $0.00 | 1,255,000.0000 | 420,279,879 | 2.45% | 0.01% |
| Aug. 29, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 28320 | $0.00 | 2,380,687.0000 | 420,279,879 | 1.20% | 0.01% |
| Aug. 29, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 75000 | $0.00 | 1,225,000.0000 | 420,279,879 | 5.77% | 0.02% |
| Aug. 26, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 30000 | $0.00 | 1,300,000.0000 | 420,279,879 | 2.36% | 0.01% |
| Aug. 22, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 1,270,000.0000 | 420,279,879 | 7.30% | 0.02% |
| Aug. 22, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 37760 | $0.00 | 2,352,367.0000 | 420,279,879 | 1.63% | 0.01% |
| Aug. 8, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,370,000.0000 | 420,279,879 | 3.52% | 0.01% |
| Aug. 8, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 18880 | $0.00 | 2,314,607.0000 | 420,279,879 | 0.82% | 0.00% |
| July 18, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 62303 | $0.00 | 2,295,727.0000 | 420,279,879 | 2.79% | 0.01% |
| July 18, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 165000 | $0.00 | 1,420,000.0000 | 420,279,879 | 10.41% | 0.04% |
| June 26, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 325000 | $0.00 | 1,585,000.0000 | 420,279,879 | 17.02% | 0.08% |
| June 26, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 122692 | $0.00 | 2,233,424.0000 | 420,279,879 | 5.81% | 0.03% |
| June 20, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,910,000.0000 | 420,279,879 | 2.55% | 0.01% |
| June 20, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 18880 | $0.00 | 2,110,732.0000 | 420,279,879 | 0.90% | 0.00% |
| June 5, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 25000 | $0.00 | 1,960,000.0000 | 420,279,879 | 1.29% | 0.01% |
| May 23, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 85000 | $0.00 | 1,935,000.0000 | 420,279,879 | 4.59% | 0.02% |
| May 15, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 60000 | $0.00 | 1,850,000.0000 | 420,279,879 | 3.35% | 0.01% |
| May 7, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,790,000.0000 | 420,279,879 | 2.87% | 0.01% |
| April 29, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 18876 | $0.00 | 2,091,852.0000 | 420,279,879 | 0.91% | 0.00% |
| April 29, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,740,000.0000 | 420,279,879 | 2.79% | 0.01% |
| April 29, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 80000 | $0.00 | 1,790,000.0000 | 420,279,879 | 4.68% | 0.02% |
| April 19, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 25000 | $0.00 | 1,710,000.0000 | 420,279,879 | 1.44% | 0.01% |
| April 19, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 9438 | $0.00 | 2,072,976.0000 | 420,279,879 | 0.46% | 0.00% |
| April 11, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 7551 | $0.00 | 2,063,538.0000 | 420,279,879 | 0.37% | 0.00% |
| April 11, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 20000 | $0.00 | 1,735,000.0000 | 420,279,879 | 1.14% | 0.00% |
| April 4, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 90000 | $0.00 | 1,755,000.0000 | 420,279,879 | 5.41% | 0.02% |
| March 26, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 400000 | $0.00 | 1,665,000.0000 | 420,279,879 | 19.37% | 0.10% |
| March 26, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 150975 | $0.00 | 2,055,987.0000 | 420,279,879 | 7.93% | 0.04% |
| March 21, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 25000 | $0.00 | 2,065,000.0000 | 0 | 1.20% | 0.00% |
| March 21, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 9436 | $0.00 | 1,905,012.0000 | 0 | 0.50% | 0.00% |
| March 20, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 130000 | $0.00 | 2,090,000.0000 | 0 | 6.63% | 0.00% |
| Feb. 27, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 180000 | $0.00 | 1,960,000.0000 | 0 | 8.41% | 0.00% |
| Feb. 27, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 67953 | $0.00 | 1,895,576.0000 | 0 | 3.72% | 0.00% |
| Feb. 20, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 125000 | $0.00 | 2,140,000.0000 | 0 | 6.20% | 0.00% |
| Feb. 15, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 27989 | $0.00 | 1,827,623.0000 | 0 | 1.56% | 0.00% |
| Feb. 15, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 75000 | $0.00 | 2,015,000.0000 | 0 | 3.59% | 0.00% |
| Jan. 30, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 2,090,000.0000 | 0 | 5.03% | 0.00% |
| Jan. 30, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 51290 | $0.00 | 1,799,634.0000 | 0 | 2.93% | 0.00% |
| Jan. 30, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 135000 | $0.00 | 1,990,000.0000 | 0 | 6.35% | 0.00% |
| Jan. 16, 2025 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 2,125,000.0000 | 0 | 4.94% | 0.00% |
| Dec. 28, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 37760 | $0.00 | 1,748,344.0000 | 0 | 2.21% | 0.00% |
| Dec. 28, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 2,025,000.0000 | 0 | 4.71% | 0.00% |
| Dec. 2, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | Stock Options (Right to Buy) | 25470215 | $0.00 | 25,470,215.0000 | 0 | 9999.99% | 0.00% |
| Nov. 29, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 2,125,000.0000 | 0 | 2.30% | 0.00% |
| Nov. 29, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 18880 | $0.00 | 1,710,584.0000 | 0 | 1.12% | 0.00% |
| Nov. 22, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | P | Series D-1 Convertible Preferred Stock | 80365 | $2.86 | 1,691,704.0000 | 0 | 4.99% | 0.00% |
| Oct. 16, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 2,175,000.0000 | 0 | 2.35% | 0.00% |
| Sept. 30, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 175000 | $0.00 | 2,125,000.0000 | 0 | 8.97% | 0.00% |
| Sept. 30, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | Series D-1 Convertible Preferred Stock | 168367 | $0.00 | 1,611,339.0000 | 0 | 11.67% | 0.00% |
| Sept. 19, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 1,950,000.0000 | 0 | 5.41% | 0.00% |
| Aug. 29, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 75000 | $0.00 | 1,850,000.0000 | 0 | 4.23% | 0.00% |
| Aug. 22, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 1,775,000.0000 | 0 | 5.97% | 0.00% |
| Aug. 8, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,675,000.0000 | 0 | 3.08% | 0.00% |
| Aug. 3, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 28320 | $0.00 | 1,442,972.0000 | 0 | 2.00% | 0.00% |
| Aug. 3, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 75000 | $0.00 | 1,625,000.0000 | 0 | 4.41% | 0.00% |
| July 20, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 47199 | $0.00 | 1,414,652.0000 | 0 | 3.45% | 0.00% |
| July 20, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 125000 | $0.00 | 1,700,000.0000 | 0 | 6.85% | 0.00% |
| July 18, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 165000 | $0.00 | 1,825,000.0000 | 0 | 9.94% | 0.00% |
| June 26, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 325000 | $0.00 | 1,785,000.0000 | 0 | 22.26% | 0.00% |
| June 30, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 47180 | $0.00 | 1,367,453.0000 | 0 | 3.57% | 0.00% |
| June 30, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 125000 | $0.00 | 1,660,000.0000 | 0 | 7.00% | 0.00% |
| June 20, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,460,000.0000 | 0 | 3.55% | 0.00% |
| June 15, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 125000 | $0.00 | 1,410,000.0000 | 0 | 8.14% | 0.00% |
| June 15, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 47190 | $0.00 | 1,320,273.0000 | 0 | 3.71% | 0.00% |
| May 26, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 18876 | $0.00 | 1,273,083.0000 | 0 | 1.51% | 0.00% |
| May 26, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,535,000.0000 | 0 | 3.15% | 0.00% |
| May 12, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 200000 | $0.00 | 1,585,000.0000 | 0 | 11.20% | 0.00% |
| May 12, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 75503 | $0.00 | 1,254,207.0000 | 0 | 6.41% | 0.00% |
| April 29, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | A | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,785,000.0000 | 0 | 2.88% | 0.00% |
| April 25, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 1,735,000.0000 | 0 | 5.45% | 0.00% |
| April 25, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | CEO | M | Series D-1 Convertible Preferred Stock | 37752 | $0.00 | 1,178,704.0000 | 0 | 3.31% | 0.00% |
| April 19, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 25000 | $0.00 | 1,835,000.0000 | 0 | 1.38% | 0.00% |
| April 11, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 20000 | $0.00 | 1,810,000.0000 | 0 | 1.12% | 0.00% |
| April 6, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 47190 | $0.00 | 1,140,952.0000 | 0 | 4.31% | 0.00% |
| April 6, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 125000 | $0.00 | 1,790,000.0000 | 0 | 6.53% | 0.00% |
| March 26, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 400000 | $400000.00 | 1,915,000.0000 | 0 | 26.40% | 0.00% |
| March 21, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 25000 | $25000.00 | 1,515,000.0000 | 0 | 1.68% | 0.00% |
| March 17, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 47190 | $0.00 | 1,093,762.0000 | 0 | 4.51% | 0.00% |
| March 17, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 125000 | $0.00 | 1,490,000.0000 | 0 | 7.74% | 0.00% |
| Feb. 27, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 180000 | $180000.00 | 1,615,000.0000 | 0 | 12.54% | 0.00% |
| Feb. 27, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 1,435,000.0000 | 0 | 6.51% | 0.00% |
| Feb. 27, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 37744 | $0.00 | 1,046,572.0000 | 0 | 3.74% | 0.00% |
| Feb. 17, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 125000 | $0.00 | 1,535,000.0000 | 0 | 7.53% | 0.00% |
| Feb. 17, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 47180 | $0.00 | 1,008,828.0000 | 0 | 4.91% | 0.00% |
| Feb. 15, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 75000 | $75000.00 | 1,660,000.0000 | 0 | 4.73% | 0.00% |
| Jan. 30, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 135000 | $135000.00 | 1,585,000.0000 | 0 | 9.31% | 0.00% |
| Jan. 26, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 47180 | $0.00 | 961,648.0000 | 0 | 5.16% | 0.00% |
| Jan. 26, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 125000 | $0.00 | 1,450,000.0000 | 0 | 7.94% | 0.00% |
| Jan. 12, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 125000 | $0.00 | 1,575,000.0000 | 0 | 7.35% | 0.00% |
| Jan. 12, 2024 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 47180 | $0.00 | 914,468.0000 | 0 | 5.44% | 0.00% |
| Dec. 28, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 100000 | $100000.00 | 1,675,000.0000 | 0 | 6.35% | 0.00% |
| Dec. 22, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 25000 | $0.00 | 1,575,000.0000 | 0 | 1.56% | 0.00% |
| Dec. 22, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 9440 | $0.00 | 876,728.0000 | 0 | 1.09% | 0.00% |
| Dec. 19, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 1,600,000.0000 | 0 | 5.88% | 0.00% |
| Dec. 19, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 37760 | $0.00 | 867,288.0000 | 0 | 4.55% | 0.00% |
| Dec. 2, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 56628 | $0.00 | 829,528.0000 | 0 | 7.33% | 0.00% |
| Dec. 2, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 150000 | $0.00 | 1,700,000.0000 | 0 | 8.11% | 0.00% |
| Nov. 29, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 50000 | $50000.00 | 1,850,000.0000 | 0 | 2.78% | 0.00% |
| Nov. 15, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 9440 | $0.00 | 772,920.0000 | 0 | 1.24% | 0.00% |
| Nov. 15, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 25000 | $0.00 | 1,800,000.0000 | 0 | 1.37% | 0.00% |
| Nov. 8, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 1,825,000.0000 | 0 | 5.19% | 0.00% |
| Nov. 8, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 37744 | $0.00 | 763,480.0000 | 0 | 5.20% | 0.00% |
| Nov. 1, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 13216 | $0.00 | 725,736.0000 | 0 | 1.85% | 0.00% |
| Nov. 1, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 35000 | $0.00 | 1,925,000.0000 | 0 | 1.79% | 0.00% |
| Oct. 27, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 2832 | $0.00 | 712,520.0000 | 0 | 0.40% | 0.00% |
| Oct. 27, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 7500 | $0.00 | 1,960,000.0000 | 0 | 0.38% | 0.00% |
| Oct. 14, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 50000 | $0.00 | 1,967,500.0000 | 0 | 2.48% | 0.00% |
| Oct. 3, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | P | Series D-1 Convertible Preferred Stock | 19311 | $2.86 | 690,800.0000 | 0 | 2.88% | 0.00% |
| Oct. 14, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 18888 | $0.00 | 709,688.0000 | 0 | 2.73% | 0.00% |
| Sept. 23, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 75000 | $0.00 | 2,127,500.0000 | 0 | 3.41% | 0.00% |
| Sept. 30, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 110000 | $0.00 | 2,017,500.0000 | 0 | 5.17% | 0.00% |
| Sept. 1, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 37760 | $0.00 | 601,651.0000 | 0 | 6.70% | 0.00% |
| Sept. 23, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 28320 | $0.00 | 629,971.0000 | 0 | 4.71% | 0.00% |
| Sept. 30, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 41518 | $0.00 | 671,489.0000 | 0 | 6.59% | 0.00% |
| Sept. 1, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 100000 | $0.00 | 0.0000 | 0 | 100.00% | 0.00% |
| Sept. 1, 2022 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 100000 | $100000.00 | 100,000.0000 | 0 | 9999.99% | 0.00% |
| Aug. 3, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 75000 | $75000.00 | 2,202,500.0000 | 0 | 3.53% | 0.00% |
| July 28, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 81067 | $0.00 | 100,000.0000 | 0 | 44.77% | 0.00% |
| July 28, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 28326 | $0.00 | 563,891.0000 | 0 | 5.29% | 0.00% |
| July 24, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | 8% Unsecured Convertible Promissory Note | 162100 | $0.00 | 75,000.0000 | 0 | 68.37% | 0.00% |
| July 24, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | M | Series D-1 Convertible Preferred Stock | 56639 | $0.00 | 535,565.0000 | 0 | 11.83% | 0.00% |
| July 20, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 125000 | $125000.00 | 2,127,500.0000 | 0 | 6.24% | 0.00% |
| June 30, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 125000 | $125000.00 | 2,002,500.0000 | 0 | 6.66% | 0.00% |
| June 15, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 125000 | $125000.00 | 1,877,500.0000 | 0 | 7.13% | 0.00% |
| May 26, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 50000 | $50000.00 | 1,752,500.0000 | 0 | 2.94% | 0.00% |
| May 12, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 200000 | $200000.00 | 1,702,500.0000 | 0 | 13.31% | 0.00% |
| April 25, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 100000 | $100000.00 | 1,502,500.0000 | 0 | 7.13% | 0.00% |
| April 6, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 125000 | $125000.00 | 1,402,500.0000 | 0 | 9.78% | 0.00% |
| March 17, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 125000 | $125000.00 | 1,277,500.0000 | 0 | 10.85% | 0.00% |
| Feb. 27, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 100000 | $100000.00 | 1,152,500.0000 | 0 | 9.50% | 0.00% |
| Feb. 17, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 125000 | $125000.00 | 1,052,500.0000 | 0 | 13.48% | 0.00% |
| Jan. 26, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 125000 | $125000.00 | 927,500.0000 | 0 | 15.58% | 0.00% |
| Jan. 12, 2023 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 125000 | $125000.00 | 802,500.0000 | 0 | 18.45% | 0.00% |
| Dec. 22, 2022 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 25000 | $25000.00 | 677,500.0000 | 0 | 3.83% | 0.00% |
| Dec. 19, 2022 | PROVECTUS BIOPHARMACEUTICALS, INC. | $PVCT | Pershing Edward | Director | A | 8% Unsecured Convertible Promissory Note | 100000 | $100000.00 | 652,500.0000 | 0 | 18.10% | 0.00% |